Clinical Chemistry

  • Arndt T., van der Meijden B.B., Wielders J.P.M., (2008) Atypical serum transferrin isoform distribution in liver cirrhosis studied by HPLC, capillary electrophoresis and transferrin genotyping. Clinica Chimica Acta, 394(1-2), 42-46. PubMed
  • Helander, A., Husa, A., & Jeppsson, J.O., (2003) Improved HPLC method for carbohydrate-deficient transferrin in serum. Clinical Chemistry, 49(11), 1881-1890. PubMed
  • Jeppsson, J.O., Arndt, T., Schellenberg, F., Wielders, J.P., Anton, R.F., Whitfield, J.B., & Helander, A., (IFCC-WG-CDT), (2007) Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method. Clinical Chemistry and Laboratory Medicine, 45(4), 558-562. PubMed
  • Helander, A., Kenan Moden N. (2013) Effect of Transferrin Glycation on the Use of Carbohydrate-Deficient Transferrin as an Alcohol Biomarker. Alcohol and Alcoholism, 1-5 PubMed

Addiction Specialists

  • Anton R. F., Lieber C., Tabakoff B., & CDTect Study Group, (2002). Carbohydrate-deficient transferrin and gamma-Glutamyltransferase for the detection and monitoring of alcohol use: Results from a multisite study. Alcoholism: Clinical and Experimental Research, 26(8), 1215-1222. PubMed
  • Center for Substance Abuse Treatment, (2006). The role of biomarkers in the treatment of alcohol use disorders. Substance Abuse Treatment Advisory, 5(4), 1-8. 
  • Cluver, J. S., Miller, P.M., & Anton, R. F., (2007). Case studies of the utility of serum carbohydrate-deficient transferrin (%CDT) in the clinical management of alcoholics. Journal of Addiction Medicine, 1(1), 44-47.
  • Fleming, M. F., Anton, R. F., & Spies, C. D., (2004). A review of genetic, biological, pharmacological, and clinical factors that affect carbohydrate-deficient transferrin levels. Alcoholism: Clinical and Experimental Research, 28(9), 1347-1355. PubMed
  • Miller, P. M., Dominick, C. S., & Anton, R. F., (2004). Carbohydrate-deficient transferrin test: A tool for detecting alcohol abuse. Current Psychiatry, 5(6), 80-87.

Surgery & Internal Medicine

  • Dillie, K. S., Mundt, M., French, M. T., & Fleming, M. F., (2005). Cost-benefit analysis of a new alcohol biomarker, carbohydrate-deficient transferrin, in a chronic illness primary care sample. Alcoholism: Clinical And Experimental Research, 29(11), 2008-2014. PubMed
  • Miller, P. M., & Anton, R. F., (2004). Biochemical alcohol screening in primary healthcare. Addictive Behaviors, 29(7), 1427-1437. PubMed
  • Miller, P. M., Spies, C., Neumann, T., Javos, M. A., Hoyumpa, A. M., Roache, J., Webb, A., Kashi, M., Sharkey, F. E., Anton, R. F., Egan, B. M., Basile, J., Nguyen, S., Fleming, M. F., Dillie, K. S., (2006). Alcohol biomarker screening in medical and surgical settings. Alcoholism: Clinical and Experimental Research, 30(2), 185-193. PubMed
  • Spies, C. D., Kissner, M., Neumann, T., Blum, S., Voigt, C., Funk, T., Runkel, N., & Pragst, F., (1998). Elevated carbohydrate-deficient transferrin predicts prolonged intensive care unit stay in traumatized men. Alcohol & Alcoholism, 33(6), 661-669. PubMed